Literature DB >> 12523624

Multiple drug-resistant Mycobacterium tuberculosis: evidence for changing fitness following passage through human hosts.

Stephen H Gillespie1, Owen J Billington, Aodhan Breathnach, Timothy D McHugh.   

Abstract

Recent studies have shown a difference in the genotype of resistant bacteria following passage in animals compared to those passaged in vitro. This suggests that organisms rapidly adapt to their environment of growth. We sought to investigate whether this phenomenon occurred in human infection and whether changes could be detected in the fitness (growth velocity) of isolates transmitted between human hosts. Isogenic strains of Mycobacterium tuberculosis were obtained from a well-documented hospital outbreak. The subjects included those who were HIV seropositive and immunocompromised. The relative fitness of each sample was measured using growth competition in vitro. The results confirmed that our method of measuring fitness was not influenced by the storage conditions of the isolates, and demonstrated that the fitness of genetically similar isolates obtained from different patients in the outbreak differed significantly, as reflected in the growth velocity of the strains. This study provides the first evidence that multiple drug resistant M. tuberculosis strains adapt to the environment of their human host.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12523624     DOI: 10.1089/10766290260469534

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  13 in total

Review 1.  Antibiotic resistance mechanisms in M. tuberculosis: an update.

Authors:  Liem Nguyen
Journal:  Arch Toxicol       Date:  2016-05-09       Impact factor: 5.153

Review 2.  Antibiotic resistance and its cost: is it possible to reverse resistance?

Authors:  Dan I Andersson; Diarmaid Hughes
Journal:  Nat Rev Microbiol       Date:  2010-03-08       Impact factor: 60.633

3.  Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis.

Authors:  Rinat Sergeev; Caroline Colijn; Megan Murray; Ted Cohen
Journal:  Sci Transl Med       Date:  2012-05-23       Impact factor: 17.956

4.  Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure.

Authors:  Naidan Luo; Sonia Pereira; Orhan Sahin; Jun Lin; Shouxiong Huang; Linda Michel; Qijing Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-05       Impact factor: 11.205

5.  Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results.

Authors:  A Van Deun; L Barrera; I Bastian; L Fattorini; H Hoffmann; K M Kam; L Rigouts; S Rüsch-Gerdes; A Wright
Journal:  J Clin Microbiol       Date:  2009-09-16       Impact factor: 5.948

Review 6.  Molecular biology of drug resistance in Mycobacterium tuberculosis.

Authors:  Tasha Smith; Kerstin A Wolff; Liem Nguyen
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

7.  A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture.

Authors:  Emmanuel Chigutsa; Kashyap Patel; Paolo Denti; Marianne Visser; Gary Maartens; Carl M J Kirkpatrick; Helen McIlleron; Mats O Karlsson
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

Review 8.  The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin?

Authors:  Anastasia Koch; Valerie Mizrahi; Digby F Warner
Journal:  Emerg Microbes Infect       Date:  2014-03-12       Impact factor: 7.163

Review 9.  Limits to compensatory adaptation and the persistence of antibiotic resistance in pathogenic bacteria.

Authors:  R Craig MacLean; Tom Vogwill
Journal:  Evol Med Public Health       Date:  2014-12-21

Review 10.  Reducing the risk of tuberculosis transmission for HCWs in high incidence settings.

Authors:  Ana Paleckyte; Oshani Dissanayake; Stella Mpagama; Marc C Lipman; Timothy D McHugh
Journal:  Antimicrob Resist Infect Control       Date:  2021-07-19       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.